These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 11060742

  • 1. Small molecule alpha(v) integrin antagonists: novel anticancer agents.
    Kerr JS, Slee AM, Mousa SA.
    Expert Opin Investig Drugs; 2000 Jun; 9(6):1271-9. PubMed ID: 11060742
    [Abstract] [Full Text] [Related]

  • 2. Small molecule antagonists of integrin receptors.
    Perdih A, Dolenc MS.
    Curr Med Chem; 2010 Jun; 17(22):2371-92. PubMed ID: 20491638
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alpha(v)beta(3) integrin in angiogenesis and restenosis.
    Kerr JS, Mousa SA, Slee AM.
    Drug News Perspect; 2001 Apr; 14(3):143-50. PubMed ID: 12819820
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment.
    Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X.
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):143-58. PubMed ID: 18221059
    [Abstract] [Full Text] [Related]

  • 9. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
    Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS.
    Angiogenesis; 2003 Jun; 6(2):105-19. PubMed ID: 14739617
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D, Manzoni L, Corno C, Perego P.
    Recent Pat Anticancer Drug Discov; 2017 Jun; 12(2):148-168. PubMed ID: 28164756
    [Abstract] [Full Text] [Related]

  • 14. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL, Jones D, Taylor G, Jaworski K, Kelly DJ, Ludbrook SB, Willette RN, Kumar S, Gilbert RE.
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
    Sheldrake HM, Patterson LH.
    J Med Chem; 2014 Aug 14; 57(15):6301-15. PubMed ID: 24568695
    [Abstract] [Full Text] [Related]

  • 19. alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.
    Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE.
    Int J Cancer; 2002 Apr 10; 98(5):690-7. PubMed ID: 11920637
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.